Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VKTX
SELLViking Therapeutics, Inc. · Healthcare · United States · $4.0B · Avg Vol: $91M/d
COMPANY DESCRIPTION
Viking Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company's pipeline includes drug candidates for conditions such as obesity, diabetes, and rare genetic diseases, leveraging its expertise in small molecule therapeutics. Viking's competitive advantage stems from its proprietary drug candidates and promising clinical data in areas with high unmet medical need.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.90 | -0.91 | -1.01 | -3.19 | — | -4.07 | -4.72 | -4.57 | — |
| Shares | 78.3M | 100.1M | 111.6M | 114.8M | +46.7% | 116.1M | — | — | — |
| Debt | 1.6M | 1.3M | 1.1M | 0.1M | -55.6% | — | — | — | — |
| Equity | 145.3M | 348.4M | 880.3M | 639.1M | 63.8% | — | — | — | — |
| Op CF | -48.4M | -73.4M | -87.8M | -278.7M | — | -340.3M | — | — | — |
| Inv CF | 54.8M | -179.1M | -553.4M | 341.4M | — | — | — | — | — |
| Fin CF | 4.2M | 271.4M | 612.5M | 76.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VKTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VKTX | Viking Therapeutics, Inc.(you) | $4.0B | 20 | SELL |
| RCUS | Arcus Biosciences, Inc. | $3.6B | 22 | SELL |
| ALMS | Alumis Inc. | $3.6B | 22 | SELL |
| DNLI | Denali Therapeutics Inc. | $3.7B | 24 | SELL |
| CELC | Celcuity Inc. | $4.0B | 14 | STRONG SELL |
| LEGN | Legend Biotech Corporation | $4.3B | 27 | SELL |
| GPCR | Structure Therapeutics Inc. | $3.5B | 15 | STRONG SELL |
| CAI | Caris Life Sciences, Inc. | $4.4B | 27 | SELL |
| IRON | Disc Medicine, Inc. | $2.8B | 22 | SELL |
| IDYA | IDEAYA Biosciences, Inc. | $3.4B | 27 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.6%